.jpg)
.jpg)
.jpg)
Most Accessed Article: Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
...
Wednesday, December 28, 2016
Wednesday, December 21, 2016
Wednesday, December 14, 2016
Thursday, December 8, 2016
Wednesday, November 30, 2016
Highlighted Article: Developing Antitumor Magnetic Hyperthermia: Principles, Materials and Devices
Highlighted Article: Developing Antitumor Magnetic Hyperthermia: Principles, Materials and Devices
...
Thursday, November 24, 2016
Monday, November 21, 2016
Tuesday, November 8, 2016
Call For Paper
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of
Recent Patents on Anti-Cancer Drug Discovery
...
Wednesday, November 2, 2016
Highlighted Article: Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Author(s):
Zsuzsanna Suba Pages 254 - 266 ( 13 )
Abstract:
Background: Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures.
Objective: Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration...
Monday, October 24, 2016
Most Cited Article: HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
HSP90 Inhibitors: Current
Development and Potential in Cancer Therapy
Author(s):
Katerina Sidera and Evangelia PatsavoudiPages 1-20 (20)
Abstract:
In the last decade, the molecular chaperone HSP90
has emerged as an important target in cancer therapeutics and has subsequently
become the focus of several drug discovery and development efforts. The
first-in-class HSP90 inhibitor 17-AAG entered into Phase I clinical trial in
1999. Today 13 HSP90 inhibitors representing multiple drug classes, with
different modes of action, are undergoing clinical...
Tuesday, October 18, 2016
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery*
Article Details
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage
and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving
Surgery*
[ Vol. 11 ,
Issue. 3 ]
Author(s):
Zsuzsanna SubaPages 254-266 (13)
Abstract:
Background: Results of long-term studies justify that the rate of breast cancer
recurrence and tumor-related mortality remains quite unpredictable, regardless
of the use of any current therapeutic measures.
Objective: Since the application
of standard therapies, such as surgery, radiation,...
Monday, October 10, 2016
Open Access Plus ::: Recent Patents on Anti-Cancer Drug Discovery
Open Access Plus ::: Recent Patents on Anti-Cancer Drug Discovery
Circulatory Estrogen Level Protects Against Breast Cancer in Obese WomenZsuzsanna Suba
Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing...
Tuesday, October 4, 2016
Most cited articles from the jorunal ‘Recent Patents on Anti-Cancer Drug Discovery’
Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Author(s): Xuan Yuan, Bacui Yu, Yanming Wang, Jiangtao Jiang, Liangliang Liu, Hong Zhao, Wang Qi and Qiusheng Zheng.
Abstract: Isoliquiritigenin (ISL), a licorice chalconoid, is a bioactive agent with chemopreventive potential that has been patented for tumor treatment in China. This study investigated the mechanisms of ISL-induced apoptosis in ovarian carcinoma SKOV-3 cells. Cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium...
New Issue::: Recent Patents on Anti-Cancer Drug Discovery, 11 Issue 1
Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles, and guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs & targets. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal...
Video presentation on the journal ‘Recent Patents on Anti-Cancer Drug Discovery ‘
Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles, and guest edited thematic issues on recent patents in the field of anti-cancer drug discovery.
Details here: http://bit.ly/1i3VfD1
courtesy by : https://benthamsciencepublishers.wordpress.com/2015/10/06/video-presentation-on-the-journal-recent-patents-on-anti-cancer-drug-discover...
Last published issue of 2015 of the journal ‘Recent Patents on Anti-Cancer Drug Discovery’ is now available online
Recent Patents on Anti-Cancer Drug Discovery,Volume 10–Number 3
Meet Our Editorial Board Member:, 10(3): 243Patrick Legembre.
pH Gradient Reversal: An Emerging Hallmark of Cancers,10(3): 244 – 258Mohit Sharma, Madhusudan Astekar, Sonal Soi, Bhari S. Manjunatha,Devi C. Shetty and Raghu Radhakrishnan.
Cabozantinib in Thyroid Cancer
, 10(3): 259 – 269
Poupak Fallahi, Silvia M. Ferrari, Flavia Di Bari, Gabriele Materazzi,Salvatore Benvenga, Paolo Miccoli and Alessandro...
Friday, August 12, 2016
Friday, June 24, 2016
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Author(s):
Sarah Shirley, Alexandre Morizot and Olivier MicheauPages 311-323 (13)
Abstract:
The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present...
Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Author(s):
Zsuzsanna SubaPages 154-167 (14)
Abstract:
Literary data suggest apparently ambiguous interaction between menopausal status and obesity-associated breast cancer risk based on the principle of the carcinogenic capacity of estrogen. Before menopause, breast cancer incidence is relatively low and adiposity is erroneously regarded as a protective factor against this tumor conferred by the obesity associated defective estrogen-synthesis. By contrast, in postmenopausal cases, obesity presents a strong risk factor for breast cancer being...
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Author(s):
Zsuzsanna SubaPages 1-13 (13)
Abstract:
Background. Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures.
Objective. Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration does not work as might be expected; our therapeutic practice requires thorough rethinking.
Method. Published long-term therapeutic results on breast cancer...
